Business Wire
24 Aug 2026, 06:36 UTC · 2h ago
NewsImpactScreener rates every claim in this story for market impact and maps it to the tickers most exposed.
What the story claims
3 claims · each scored for market impact
Japan's MHLW approved ORZEYFUL (oveporexton) for the treatment of narcolepsy type 1 in adults. — Regulatory approval opens a new revenue stream and allows for the commercial launch of a new product.
+0.60ORZEYFUL is the only medicine indicated in Japan to treat narcolepsy type 1 holistically rather than treating individual symptoms. — A unique competitive positioning as a holistic treatment may lead to higher market share and pricing power.
+0.40ORZEYFUL is a first-in-class oral orexin receptor 2 (OX2R) agonist. — First-in-class status suggests a novel mechanism of action which can be a long-term catalyst for the company's pipeline value.
+0.20Which stocks this story touches
Continue reading
6 related stories
Search tags
The company received regulatory approval in Japan for a first-in-class treatment for narcolepsy type 1.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
How the impact breaks down
Where the story's weight lands
Stocks most exposed
Modeled from each name's sensitivity to this story
No stock impact ranking available yet.
Reuters
1h ago
